Safe Bulkers, Inc. Declares Quarterly Dividend on its 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares; 8.00% Series D Cumulative Redeemable Perpetual Preferred Shares

Safe Bulkers, Inc. Declares Quarterly Dividend on its 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares; 8.00% Series D Cumulative Redeemable Perpetual Preferred Shares GlobeNewswire January 02, 2026 MONACO, Jan. 02, 2026 (GLOBE NEWSWIRE) — Safe Bulkers, Inc. (the “Company”) (NYSE: SB), an international provider of marine drybulk transportation services, announced today that the Company's […]

Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026

Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026 GlobeNewswire January 02, 2026 TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2025 financial and

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire January 02, 2026 FOSTER CITY, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of January 1, 2026 equity inducement awards to two

RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference

RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference GlobeNewswire January 02, 2026 ALISO VIEJO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) — RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference. RxSight's management

Horizon Bancorp, Inc. Announces Conference Call to Review Fourth Quarter Results on January 22

Horizon Bancorp, Inc. Announces Conference Call to Review Fourth Quarter Results on January 22 GlobeNewswire January 02, 2026 MICHIGAN CITY, Ind., Jan. 02, 2026 (GLOBE NEWSWIRE) — Horizon Bancorp, Inc. (“Horizon” or the “Company”) will host a conference call at 7:30 a.m. CT on Thursday, January 22, 2026, to review its fourth quarter 2025 financial

Meridianbet (GMGI) CEO Featured in Jerusalem Post: “We Are Not a Promise-Based Company, We Are an Execution-Based Company”

(NASDAQ:GMGI), VALLETTA, Malta, Jan. 02, 2026 (GLOBE NEWSWIRE) — Meridianbet, the sports betting and gaming operator and subsidiary of Golden Matrix Group Inc. (NASDAQ: GMGI), today announced that CEO Zoran Milosevic was featured in an in-depth profile published by The Jerusalem Post, one of the world's leading international news organizations. The profile, titled “From gaming

Meridianbet (GMGI) CEO Featured in Jerusalem Post: “We Are Not a Promise-Based Company, We Are an Execution-Based Company”

Meridianbet (GMGI) CEO Featured in Jerusalem Post: “We Are Not a Promise-Based Company, We Are an Execution-Based Company” GlobeNewswire January 02, 2026 VALLETTA, Malta, Jan. 02, 2026 (GLOBE NEWSWIRE) — Meridianbet, the sports betting and gaming operator and subsidiary of Golden Matrix Group Inc. (NASDAQ: GMGI), today announced that CEO Zoran Milosevic was featured in

GH Research to Announce IND Status for GH001

(NasdaqGM:GHRS), DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported that it will provide an update on the status of its Investigational New Drug Application (IND) for GH001 with the U.S. Food

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(NasdaqGM:NTLA), CAMBRIDGE, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on January 1, 2026, it awarded inducement grants to two new employees under Intellia's 2024 Inducement Plan as a material inducement to employment. The inducement grants

Scroll to Top